Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Psilocybin-assisted therapy for cancer-related anxiety in metastatic cancer
NCT05847686Phase 2Completed
- Sponsor
- University of Washington
- Start
- Jun 2023
- Primary completion
- Apr 2024
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of psilocybin in anxiety disorder, major depressive disorder (MDD), sponsored by University of Washington. Started Jun 2023; status: completed.
02
Drugs
psilocybin
03
Conditions
anxiety disordermajor depressive disorder (MDD)
Beyond the preview
Go deeper on NCT05847686.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05847686.